论文部分内容阅读
体外佩带式起搏器作为永久性起搏器缺点甚多,因此,只适用于临时性起搏。目前体内埋藏式心脏起搏器已成为临床上永久性心脏起搏的主要方法。我院自1979年7月～1983年6月共装埋藏式心脏起搏器25例,因其中4例随访时间较短,兹仅报告21例如下: 一、临床资料本组共21例,男11例,女10例;年龄21～81岁,平均58.6岁,大于60岁11例。冠心病17例(合并高血压5例),病毒性心肌炎3例,心肌病1例。21例中18例为完全性房室传导阻滞合并复发性心脑缺血综合征,3例为病态窦房结综合征引起反复性昏厥。6例装国产埋藏式R抑制型按需起搏器(5例南京产品,1例复旦大学产品),14例是美国制埋藏式R抑制型按需起搏品(其中2例是多功能程序控制式心脏起搏器),1例是澳大利亚制多功能程序控制式心脏起搏器。插管途径、电极和起搏器的位置:经头静脉16例(右侧10例,左侧6例),3例因头静脉细小,插管困难,改用右颈外静脉,2例因
External wearable pacemakers have many disadvantages as permanent pacemakers and are therefore only suitable for temporary pacing. At present, buried pacemaker in vivo has become the main method of clinical permanent cardiac pacing. Our hospital from July 1979 to June 1983 a total of 25 cases of implanted pacemakers, of which 4 were short-term follow-up, we only report the following 21 cases: First, the clinical data of 21 patients in this group, male 11 cases, 10 females; aged 21 to 81 years, mean 58.6 years old, more than 60 years in 11 cases. 17 cases of coronary heart disease (hypertension in 5 cases), 3 cases of viral myocarditis, cardiomyopathy in 1 case. Among 21 cases, 18 cases were complete atrioventricular block with recurrent ischemic syndrome and 3 cases were caused by sick sinus syndrome. 6 cases of domestic embedded R-controlled on-demand pacemaker (5 cases of Nanjing products, 1 cases of Fudan University products), 14 cases of the United States made buried R-inhibited on-demand products (2 cases are multi-purpose program Controlled pacemaker) and 1 case is a multi-purpose programmable pacemaker made in Australia. Intubation, electrodes and pacemaker position: 16 cases (10 cases in the right and 6 cases in the left) through the cephalic vein, 3 cases with small capillaries and difficult intubation. The right external jugular vein was used in 2 cases